

## Special Issue

# Pneumococcal Conjugate Vaccines and Prevention of Non-invasive and Invasive Pneumococcal Diseases

### Message from the Guest Editor

While PCVs has shown a tremendous efficacy against some serotypes, the vaccine responses and protection against serotype 3 remain low and therefore, a formidable challenge, despite the immense overall efficacy of PCVs. Despite the continued success of PCV immunization, nonvaccine colonization and disease-causing serotypes have emerged. However, the current cost of PCVs makes them less likely to be used extensively in developing countries where the need is the highest. This Special Issue will focus on pneumococcal anticapsular antibody responses and comprehensive analysis of serotype-specific efficacy of PCV formulations across geographies. The issue will focus on the systematic reduction of non-invasive (sinusitis, otitis media, pneumonia) and invasive serotypes after the administration of PCVs in at-risk human populations, i.e., children, the elderly and immunocompromised. The issue will also focus on nonvaccine emergent serotypes and extension of the valency of new PCVs to address emergent serotypes, as well as newer noncapsular vaccine approaches against pneumococcal diseases.

---

### Guest Editor

Dr. Nadeem Khan

Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, ND, USA

---

### Deadline for manuscript submissions

closed (31 January 2021)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/41396](https://mdpi.com/si/41396)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).